10YR企业会员
发布人：长沙上禾生物科技有限公司
发布日期:2026/7/29 19:29:34
公司官网 http://www.staherb.com/ 资质:HALAL, KOSHER等认证
☎：19573130018 杨经理（微信同号）
花旗松素以Taxifolin（二氢槲皮素，CAS 480-18-2，C₁₅H₁₂O₇，2R,3R-trans 二氢黄酮醇）为唯一核心分子，五酚羟基 + C 环饱和（区别于槲皮素双键）使其水脂兼溶、光热稳于槲皮素；活性落在强抗氧化（直接淬灭+Nrf2 内源酶双重）、抗炎（NF-κB/MAPK 双路）、耐缺氧与抗疲劳、心血管保护（内皮/抗血小板/抗 LDL 氧化）、肝保护代谢调节、神经与皮肤抗衰六条主轴，其中抗氧化与抗炎证据最一致，耐缺氧/心血管为俄欧已用方向（俄推荐 25 mg/d、EU 100 mg/d 处方背景），抗癌/神经仍为临床前。属"膳食黄酮级"非药品。
强效抗氧化——标志性主轴：直接清除 ·OH/·O₂⁻/H₂O₂/ONOO⁻/DPPH·/ABTS⁺·/脂氧 LOO·（DPPH IC₅₀ ≈63.8 μg/mL，优于 Trolox；亚油酸过氧化抑制 81% @30 μg/mL）；螯合 Fe²⁺/Cu²⁺ 阻 Fenton；激活 Nrf2/Keap1 解离→ARE→HO-1/NQO1/SOD/CAT/GPx/GCLM-GCLC↑，内源抗氧化容量升 30%–50%；穿透血脑屏障护神经元（槲皮素饱和型更易跨膜）。部分体系抗氧化指数标称 2.3×（相对 VC/VE），但属营销参照非临床终点。
2.含耐缺氧与抗疲劳：提升红细胞携氧与组织耐低氧（HIF-1α/HO-1 轴），降低运动乳酸/BUN，延长力竭时间；俄临床"Ascovertin"（Taxifolin+VC）用于放化疗氧化应激与高原耐缺氧背景。
心血管保护：改善内皮依赖舒张（eNOS-NO↑）、抑 ACE 活性（轻度降压）、抗血小板聚集、阻 ox-LDL 形成与血管平滑肌异常增殖、心肌缺血/再灌注损减（PI3K/Akt 生存信号）；IJMS 2025 综述确认对动脉粥样硬化/糖尿病心肌病有调护前景。
抗炎与免疫调节：抑 IKK/IκBα→阻 NF-κB p65 核转位；下调 MAPK（p38/JNK/ERK）；削 TNF-α/IL-6/IL-1β/PGE₂/NO/COX-2/iNOS；RAW264.7 模型显著抑 LPS 诱导 NO/PGE₂；2024 Brinkmann 等证 0.1–1 μg/mL 抑狼疮/抗磷脂综合征中性粒细胞胞外诱捕网（NETosis），20 mg/kg/d 体内减大静脉血栓——血栓炎症新方向。
肝保护与代谢调节：阻 CCl₄/乙醇/药物肝损（ALT/AST↓、胶原沉积↓、脂肪变逆转），AMPK+PI3K/Akt 调糖脂、GLUT4 转位、抑 HMG-CoA 还原酶与 FAS→降 TG/TC/LDL-C；糖尿病肾/心肌病研究级。
神经与皮肤抗衰（研究级→日化落地）：抑 BACE1 减 Aβ 聚集、PD 模型护多巴胺能神经元；日化端淬 UV-ROS、抑弹性蛋白酶/胶原酶、抑酪氨酸酶（美白）、抗糖化 AGEs，借 C 环饱和稳定性优于槲皮素。
直接淬灭：五酚羟供氢 + 螯合过渡金属，脂/水双相断链。
Nrf2/ARE 主轴：Keap1 半胱修饰→Nrf2 核转位→II 相酶与 GSH 系统上调（核心差异化于单纯 VC/VE）。
NF-κB + MAPK 双抑：炎症转录与应激 MAPK 共阻。
心血管：eNOS-NO-cGMP + ACE 轻度抑 + 抗血小板（TXA₂/PGI₂ 比） + ox-LDL 阻截。
代谢：AMPK（糖脂氧化）+ PI3K/Akt（GLUT4/生存）+ HMG-CoA 还原酶抑。
PK：口服生物利用度受糖醛酸化/硫酸化限制（天然形式 ~5%–10%），微粉化/β-CD 包合/植质体可提 2–3×；原型尿少，代谢物为葡萄糖醛酸/硫酸酯/甲基化酚酸；血脑屏障透过性优于槲皮素。
注：上禾 Staherb 该品为食品/保健食品/功能饮料/日化/医药研发级原料（非药品）。抗氧化/耐缺氧/心血管声称用 "supports antioxidant defense / hypoxia tolerance / cardiovascular wellness as part of flavonoid-rich diet"，不得写"治疗冠心病/替代他汀/治狼疮"；临床日剂量参考俄 25 mg / EU 100 mg 为处方背景，膳食补充研究多用 40–300 mg/d 标化 Taxifolin，随脂餐分 1–2 次；孕妇哺乳/<18 岁/抗凝药同服（抗血小板叠加）需医师评估；高纯单体见光渐黄，配方避光。
Taxifolin acts through its sole core molecule Taxifolin (Dihydroquercetin, CAS 480-18-2, C₁₅H₁₂O₇, 2R,3R-trans flavanonol); five phenolic OH + saturated C-ring (vs quercetin double bond) give better water-lipid solubility & photo-thermal stability than quercetin; activity lands on six axes—potent antioxidant (direct quenching + Nrf2 endogenous enzyme dual), anti-inflammatory (NF-κB/MAPK dual), hypoxia-tolerance & anti-fatigue, cardiovascular protection (endothelium/anti-platelet/ox-LDL), hepatometabolic, neuro & skin anti-aging—with antioxidant+anti-inflammatory most consistent; hypoxia/cardio already used in RU/EU prescription context (RU 25 mg/d, EU 100 mg/d), cancer/neuro still preclinical. "Dietary flavonoid tier", not drug.
Potent antioxidant — flagship: directly scavenges ·OH/·O₂⁻/H₂O₂/ONOO⁻/DPPH·/ABTS⁺·/LOO· (DPPH IC₅₀ ≈63.8 μg/mL, better than Trolox; linoleic peroxidation 81% inhib @30 μg/mL); chelates Fe²⁺/Cu²⁺ blocking Fenton; activates Nrf2/Keap1 dissociation→ARE→HO-1/NQO1/SOD/CAT/GPx/GCLM-GCLC↑, plasma TAC +30%–50%; crosses BBB (saturated C-ring eases membrane transit). Some marketing cites antioxidant index 2.3× vs VC/VE—reference not clinical endpoint.
Hypoxia-tolerance & anti-fatigue: raises RBC oxygen utility & tissue hypoxia resistance (HIF-1α/HO-1), lowers exercise lactate/BUN, extends exhaustion time; Russian "Ascovertin" (Taxifolin+VC) in chemo-radio oxidative stress & high-altitude context.
Cardiovascular protection: improves endothelium-dependent relaxation (eNOS-NO↑), mild ACE inhibition (BP↓), anti-platelet aggregation, blocks ox-LDL & vascular smooth-muscle hyperplasia, attenuates myocardial I/R via PI3K/Akt survival; IJMS 2025 review confirms promise in atherosclerosis/diabetic cardiomyopathy.
Anti-inflammatory & immune: inhibits IKK/IκBα→blocks NF-κB p65 translocation; downregulates MAPK (p38/JNK/ERK); cuts TNF-α/IL-6/IL-1β/PGE₂/NO/COX-2/iNOS; RAW264.7 LPS model strongly suppresses NO/PGE₂; Brinkmann 2024 showed 0.1–1 μg/mL inhibits lupus/APS NETosis, 20 mg/kg/d in vivo reduces large-vein thrombosis—thrombo-inflammation new angle.
Hepatoprotective & metabolic: blocks CCl₄/ethanol/drug liver injury (ALT/AST↓, collagen↓, steatosis reversed), AMPK+PI3K/Akt tunes glucose-lipid, GLUT4 translocation, HMG-CoA reductase & FAS inhibition→↓TG/TC/LDL-C; diabetic nephro-/cardio-myopathy research-grade.
Neuro & skin anti-aging (research→cosmetic landing): BACE1 inhibition ↓Aβ aggregation, PD model dopaminergic protection; cosmetic end quenches UV-ROS, inhibits elastase/collagenase, tyrosinase (whitening), anti-glycation AGEs—saturated C-ring more stable than quercetin in formulations.
Direct quenching: five phenolic-OH H-donation + transition-metal chelation, lipid/water biphasic chain-breaking.
Nrf2/ARE axis: Keap1 cysteine modification→Nrf2 nuclear translocation→phase-II & GSH system up (core differentiation from plain VC/VE).
NF-κB + MAPK dual suppression: inflammatory transcription & stress MAPK co-blocked.
Cardiovascular: eNOS-NO-cGMP + mild ACE inhibition + anti-platelet (TXA₂/PGI₂ ratio) + ox-LDL blockade.
Metabolic: AMPK (glucose-lipid oxidation) + PI3K/Akt (GLUT4/survival) + HMG-CoA reductase inhibition.
PK: oral bioavailability limited by glucuronidation/sulfation (native ~5%–10%), micronization/β-CD/phytosome raises 2–3×; little parent in urine, metabolites glucuronide/sulfate/methylated phenolics; BBB permeability better than quercetin.
Note: Staherb grade is food/nutraceutical/functional-beverage/cosmetic/pharma-R&D raw material, not a drug. Antioxidant/hypoxia/cardio claims use "supports antioxidant defense / hypoxia tolerance / cardiovascular wellness as part of flavonoid-rich diet"—never "treats CAD / replaces statin / treats lupus"; prescription context RU 25 mg / EU 100 mg/d is drug background, dietary-supplement studies mostly 40–300 mg/day standardized Taxifolin, split with fatty meals; pregnancy/lactation/<18 yr/anticoagulant co-use (anti-platelet additivity) need clinician review; high-pure monomer yellows on light, formulate light-proof.
公司官网 http://www.staherb.com/ 资质:HALAL, KOSHER等认证
☎：19573130018 杨经理（微信同号）
相关新闻资讯
